Bayer’s $7.25 Billion Roundup Settlement Wins Court Approval, Capping a Decade of Cancer Litigation
A Missouri judge has given final approval to Bayer’s $7.25 billion settlement of lawsuits alleging that its weedkiller Roundup causes cancer, a decision that could finally bring to a close litigation that has weighed on the German company for close to a decade. Judge Timothy Boyer of a state court in St. Louis ruled on Friday that the settlement was “fair, reasonable, and adequate”, according to Reuters, clearing the way for a nationwide programme that will pay tens of thousands of current and future claimants over as long as 21 years.
The settlement, which was announced in February, is designed to resolve nearly all current and future Roundup claims in the United States. Under its terms, Monsanto, the Bayer subsidiary that makes Roundup, will make declining capped annual payments into a special fund for up to 21 years, totalling as much as $7.25 billion, a figure that includes payments the company has already made. The programme covers people who say they were exposed to Roundup before 17 February 2026 and who have developed, or are later diagnosed with, non-Hodgkin lymphoma, a form of blood cancer.
Individual payouts will vary widely. According to the Associated Press, participants could receive an average of between $10,000 and $165,000, depending on how they used the product, how old they were when diagnosed and the severity of their illness. Agricultural, industrial or turf workers exposed at length to the weedkiller could receive an average of $165,000 if they were diagnosed with an aggressive form of the illness while younger than 60. Anyone diagnosed at age 78 or older would receive significantly less, with an average of $10,000. The approved settlement also includes $600 million for attorneys’ fees.
Judge Boyer overruled objections that payouts to individual cancer victims would be too low, noting that some claimants who settled earlier had been paid more. He also warned that delaying payouts could force victims, including those whose cancer is terminal, to wait “an indeterminate number of years” to be paid. In a written judgment, he said the average individual payouts are “fair and adequate” and the total dollar amount is “among the largest in the history of mass tort personal-injury class action settlements”. He added that there was a risk Bayer would have filed for bankruptcy protection if the settlement had been rejected. The decision could still be appealed.
“The court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation,” Bayer chief executive Bill Anderson said in a statement after the ruling. Christopher Seeger, a lawyer for many of the plaintiffs, said the Supreme Court’s June ruling had narrowed the ability of Roundup victims to pursue claims in court, adding: “We look forward to getting this relief into the hands of all Roundup victims as quickly as possible.”
A decade of litigation
Bayer has faced approximately 65,000 claims in US state and federal courts from people who said they developed cancer after using Roundup at home or on the job, according to Reuters. The Associated Press puts the total number of Roundup-related claims made against Bayer at about 200,000, many of them from people who used the product on residential lawns and gardens. Only a couple of dozen cases have gone before jurors, with mixed results: some juries sided with Bayer and others with plaintiffs. In one case, a Georgia jury awarded plaintiffs $2.1 billion.
The litigation arrived with Bayer’s $63 billion purchase of Monsanto in 2018, a deal that has haunted the company ever since. Bayer’s share price has fallen 46 percent since the acquisition, according to Reuters, although the shares have nearly doubled over the past year as investors have begun to price in an end to the legal overhang. Bayer had already settled much of the Roundup litigation for $10.9 billion in 2020, but it was unable to win court approval for a $1.25 billion settlement to resolve future claims. The company had previously set aside $16 billion to cover legal costs related to Roundup cases, and the new settlement is in addition to that provision.
Roundup itself has been in use for more than half a century. Monsanto, based in Missouri, debuted the weedkiller in 1974 with the chemical glyphosate as its active ingredient. The product quickly became one of the most widely used herbicides in agriculture, designed to be used with genetically modified seeds that can resist the weedkiller’s deadly effect, allowing farmers to produce more while tilling the soil less. It is also commonly applied on lawns and gardens. Bayer has long maintained that Roundup and glyphosate are safe, and that decades of studies have shown that glyphosate does not cause cancer.
That safety claim remains disputed. The World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic” in 2015. The US Environmental Protection Agency, by contrast, has determined that it is not likely to cause cancer in humans when used as directed. The scientific disagreement has never been resolved, and it sits at the heart of the thousands of lawsuits that followed Bayer’s takeover of Monsanto.
The Supreme Court ruling that changed the balance
The settlement was approved five months after the US Supreme Court handed Bayer a significant victory in June. In a 7-2 decision, the court overturned a $1.25 million jury award for a Missouri man, John Durnell, who blamed years of exposure to glyphosate in Roundup for his non-Hodgkin lymphoma. The court agreed with Bayer that a federal law regulating pesticides barred failure-to-warn claims brought under state law, undercutting a central pillar of many of the lawsuits.
The Durnell decision narrowed the path for claimants in a way that shaped everything that followed. Christopher Seeger, a lawyer for many of the plaintiffs, said the ruling narrowed the ability of Roundup victims to pursue claims in court. The Associated Press reported that litigants faced growing uncertainty while the settlement was pending, and that the Supreme Court had undercut one of the central arguments in the Roundup lawsuits: the high court ruled in June that Bayer cannot be sued in state courts on claims it failed to warn about cancer, because federal regulations do not require a cancer warning label and states are forbidden from imposing additional labelling requirements.
For many plaintiffs’ lawyers, that changed the calculation entirely. Though some attorneys for cancer patients contend the settlement payouts are too small, others argue the deal is better than getting nothing, which became a heightened likelihood after the Supreme Court ruling. In the first Roundup verdict since the Supreme Court’s precedent-setting ruling, a Missouri jury in October sided with Bayer in a case alleging design defects, negligence and fraud. The verdict “should send a strong signal” that plaintiffs “will face significant challenges” pursuing Roundup-related cancer claims in the future, said Bill Dodero, Bayer’s US general counsel and global litigation leader.
Not everyone is satisfied. Some attorneys have said the individual settlement amounts are too small and the terms too restrictive. “This settlement is the scariest, worst future settlement that’s ever been contemplated,” attorney Gerson Smoger said during a September court hearing on whether the settlement was fair. He said it locked in future claimants for decades with no chance at punitive damages, yet “kept the product that they were exposed to on the market, allowing the victims to continue to be exposed.” Lawyers for some of the Roundup victims who objected to the settlement did not immediately respond to requests for comment after the ruling, according to Reuters.
What the settlement does not cover
The approval does not end every case. The settlement excludes some lawsuits that remain pending in federal court. Bayer has said about 200 of those cases are still being litigated, and that the Supreme Court decision gave it strong defences in those proceedings. The final approval order is also subject to appeal, and any challenge could suspend payments until the appellate process concludes, pushing the start of funding into uncertain territory.
The structure of the deal matters as much as its headline figure. Because prior disbursements count against the $7.25 billion ceiling, and because the annual instalments are capped and designed to decline over time, investors should focus on the annual limits that govern cash outflow rather than the headline total alone. The agreement is intended to capture the bulk of current and possible future US claims tied to non-Hodgkin lymphoma, and the fund reaches both existing diagnoses and conditions identified within 16 years of the agreement taking effect. Beyond glyphosate, the company faces further litigation exposure, including proceedings related to polychlorinated biphenyls, or PCBs.
For Bayer, the settlement also provides financial certainty against mounting litigation costs that had led it to contemplate pulling Roundup from US agricultural markets. The company has already changed the formula for the version of Roundup sold to residential users, removing glyphosate from its new residential products. The settlement’s long payment horizon, stretching over two decades, spreads the cost in a way that the company’s balance sheet can absorb, rather than landing as a single bill.
A week of wins for Anderson
The court approval caps a significant week for Bill Anderson, who has said he wanted to contain the Roundup litigation risk by the end of this year. The Financial Times reported that the decision is a victory for the chief executive, who has made resolving the legal overhang a central plank of his turnaround plan for Bayer since taking the top job. Anderson has been trying to rebuild investor confidence in a company whose shares had been battered by the Monsanto litigation, a struggling pharmaceuticals pipeline and heavy debt.
The same week brought a second piece of good news. The US Food and Drug Administration approved asundexian, under the brand name Sunharbo, to reduce the risk of further strokes in adults who have suffered a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack. According to Bayer, it is the first approved factor XIa inhibitor, a new class of blood thinner, and the company has launched it in the United States as an orderable 50-milligram tablet. Two regulatory and legal wins in quick succession gave analysts something to work with.
Analyst sentiment has been shifting in Bayer’s favour. Berenberg lifted its price target on Bayer shares from 53.50 euros to 62.00 euros on 17 November, keeping a Hold rating. Kepler Cheuvreux lifted its price target to 69 euros from 58 euros earlier in the week while reaffirming its buy rating. The upgrades came alongside Bayer’s third-quarter 2026 results, which showed group revenue of 10.1 billion euros and earnings before interest, tax, depreciation and amortisation before special items of 1.62 billion euros. The company also raised its full-year guidance, including for EBITDA before special items, free cash flow and net financial debt, lifting its 2026 EBITDA guidance to a range of 9.8 to 10.3 billion euros.
Bayer shares slipped on Friday as a wave of selling in artificial intelligence names weighed on European equities, with Reuters linking the weakness to position unwinding around AI. The broader market move overshadowed the legal news on the day, but the company’s shares have roughly doubled over the past year from the mid-20s in euros, and the 52-week high stands at 57.84 euros.
Analysis: Why It Matters
The approval of the Roundup settlement is one of the most consequential corporate legal events of the year, and its significance extends well beyond Bayer’s share price. At its core, it is a test of whether the American legal system can still deliver compensation to people who believe a widely used product made them ill, when the highest court in the land has simultaneously narrowed the legal theories available to them. The settlement answers that question with a compromise that neither side loves and both sides can live with: guaranteed money, spread over decades, in exchange for giving up the right to keep suing.
For the claimants, the deal trades the possibility of a large jury verdict for the certainty of payment. That trade looks very different depending on where a claimant sits. A farm worker diagnosed with an aggressive form of non-Hodgkin lymphoma before the age of 60 can expect an average of $165,000. An 78-year-old diagnosed late in life can expect an average of $10,000. Those figures will strike many as modest compensation for a life-threatening illness, and the objections heard in court in September made that point forcefully. But the alternative, after the Supreme Court’s Durnell ruling, was increasingly stark: a legal landscape in which failure-to-warn claims, the backbone of the Roundup litigation, could no longer be brought in state court at all. The settlement’s defenders argue, with some force, that a guaranteed payment beats a lawsuit that may now be unwinnable.
For Bayer, the deal does something no court victory could: it puts a ceiling on the liability. The $7.25 billion figure, spread over as many as 21 years in declining annual instalments, converts an open-ended legal risk into a manageable, predictable cash outflow. That matters enormously for a company that has spent eight years living under the shadow of the Monsanto acquisition, watching its market value erode as each new jury verdict added to the bill. The settlement also protects the company’s ability to keep selling Roundup to farmers, which remains a core part of its crop science business, and it removes the threat, however remote, of a bankruptcy filing that the judge himself raised as a real possibility.
There is a wider lesson here for corporate dealmaking. The Monsanto acquisition, at $63 billion, is now widely regarded as one of the worst large acquisitions in recent corporate history, not because the underlying agricultural business was weak, but because the buyer underestimated the legal liabilities it was inheriting. Bayer paid $10.9 billion to settle much of the litigation in 2020, failed to get court approval for a $1.25 billion deal covering future claims, and has now agreed to pay up to $7.25 billion more, on top of $16 billion set aside for legal costs. The total bill for the Roundup litigation is now approaching $35 billion, more than half the price Bayer paid for Monsanto itself. Any chief executive contemplating a large acquisition in a litigious industry will be studying this case for years.
The settlement also exposes a fault line in how the United States regulates chemicals. Glyphosate is the most widely used herbicide in the world, and the two most authoritative bodies to have examined it have reached opposite conclusions: the World Health Organization’s cancer agency says it is probably carcinogenic, while the US Environmental Protection Agency says it is not likely to cause cancer when used as directed. The Supreme Court’s June ruling did not resolve that scientific dispute; it resolved a legal one, holding that federal pesticide law prevents states from requiring cancer warnings that federal regulators have not demanded. The result is a system in which the science remains contested, the warning labels remain absent, and the compensation is delivered through a court-approved fund rather than through the ordinary process of trial and verdict.
What happens next will be watched closely. The approval order can be appealed, and any appeal would freeze payments until the process concludes. The roughly 200 federal cases excluded from the settlement will continue to be litigated, and their outcomes will test whether Bayer’s defences, strengthened by the Durnell ruling, hold up in practice. The fund itself will have to administer claims for up to 16 years after it takes effect, a long administrative tail that will require careful management. And the question of whether Roundup remains on the market in its current form, or whether Bayer eventually withdraws it from American agriculture altogether, remains open.
For investors, the immediate question is whether the removal of the legal overhang allows the market to value Bayer on its operating performance rather than its courtroom exposure. The analysts who raised their price targets this week clearly think so, pointing to the raised guidance, the third-quarter results and the new stroke drug as evidence that the underlying business is turning. The shares have already doubled over the past year, suggesting that much of the optimism is priced in. But if the settlement survives appeal and the payments begin on schedule, Bayer will have closed the book on the defining crisis of its modern history, and the conversation about the company can finally move on to what it makes and sells, rather than what it owes in court.
Sources
- Reuters — “Missouri judge approves Bayer’s $7.25 billion Roundup settlement” (via LA Post)
- Associated Press — “Court approves $7.25 billion settlement with Bayer over claims Roundup weedkiller caused cancer”
- Business Wire — “Court Grants Final Approval to Roundup Class Settlement” (Bayer/Monsanto statement)
- Bloomberg Tax — “Bayer’s $7.25 Billion Roundup Settlement Approved by Judge”